Keytruda sales and marketing update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Keytruda pembrolizumab from Merck to treat advanced or metastatic PD-L1-positive non-small cell lung cancer (NSCLC) in adults who have had ≥1 chemotherapy. Patients with EGFR-positive or anaplastic lymphoma kinase (ALK)-positive disease must also have received targeted treatment. ...